Mesa Laboratories (NASDAQ:MLAB) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Mesa Laboratories (NASDAQ:MLAB) from a hold rating to a buy rating in a research note published on Saturday morning.

A number of other research firms also recently weighed in on MLAB. Wells Fargo & Company raised Mesa Laboratories from an “underweight” rating to an “equal weight” rating and reduced their price target for the stock from $100.00 to $67.00 in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Mesa Laboratories in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Mesa Laboratories presently has an average rating of “Reduce” and an average target price of $67.00.

Mesa Laboratories Trading Up 1.5%

MLAB stock opened at $76.01 on Friday. The company has a quick ratio of 0.47, a current ratio of 0.66 and a debt-to-equity ratio of 0.46. Mesa Laboratories has a twelve month low of $55.45 and a twelve month high of $155.12. The company has a market cap of $418.21 million, a P/E ratio of -542.93 and a beta of 0.89. The business has a fifty day moving average of $70.14 and a 200-day moving average of $85.07.

Mesa Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 15th. Investors of record on Friday, November 28th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, November 28th. Mesa Laboratories’s dividend payout ratio is -200.00%.

Institutional Trading of Mesa Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC raised its position in shares of Mesa Laboratories by 17,733.3% in the third quarter. Farther Finance Advisors LLC now owns 535 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 532 shares during the period. CWM LLC raised its position in Mesa Laboratories by 48.9% during the third quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 196 shares in the last quarter. State of Wyoming lifted its position in Mesa Laboratories by 501.4% in the 1st quarter. State of Wyoming now owns 427 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 356 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Mesa Laboratories in the 1st quarter valued at $67,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Mesa Laboratories by 115.3% during the second quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock valued at $74,000 after buying an additional 421 shares during the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.